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Individuals differ in their susceptibility to radiogenic cancers, and there is evidence that 
this inter-individual susceptibility extends to HZE ion-induced carcinogenesis. Three 
components of individual risk: sex, age at exposure, and prior tobacco use, are already 
incorporated into the NASA cancer risk model used to determine safe days in space for 
US astronauts. Here, we examine other risk factors that could potentially be included 
in risk calculations. These include personal and family medical history, the presence 
of pre-malignant cells that could undergo malignant transformation as a consequence 
of radiation exposure, the results from phenotypic assays of radiosensitivity, heritable 
genetic polymorphisms associated with radiosensitivity, and postflight monitoring. 
Inclusion of these additional risk or risk reduction factors has the potential to personalize 
risk estimates for individual astronauts and could influence the determination of safe 
days in space. We consider how this type of assessment could be used and explore how 
the provisions of the federal Genetic Information Non-discrimination Act could impact 
the collection, dissemination and use of this information by NASA.
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introdUCtion
In spaceflight, astronauts are exposed to a radiation environment consisting of a uniform flux of 
background galactic cosmic radiation with intermittent pulses of high energy protons from solar 
particle events. As employers, NASA must comply with the federal Occupational Safety and Health 
Act, which (among other things) requires NASA to set radiation exposure limits to protect the health 
of astronauts on space missions (1). At the time of this writing, NASA’s approach to setting permis-
sible radiation exposure limits is unique among federal agencies. The risk of developing a fatal cancer 
from radiation exposure is calculated using a regularly updated model, currently NSCR 2012 (2) 
as recently revised (3). Career exposures are limited to doses that will not result in more than a 3% 
probability of fatal cancer (risk of exposure-induced death or REID) at the 95% upper confidence 
interval of the risk calculation. For an individual astronaut, the risk calculation takes into account the 
astronaut’s age at exposure and sex, and assumes that he or she is a non-smoker. Because the risk for 
most radiation-induced cancers decreases with older ages at exposure and risks are greater in females 
than males, the effect is to allow less cumulative flight time for female and younger astronauts. 
Several reference missions, including a near Earth asteroid mission and Mars missions exceed the 
3% REID for fatal cancer; so do multiple ISS missions exceeding a total duration of about 24 months 
for male astronauts and about 18 months for female astronauts during solar minimum (3, 4). This 
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article examines whether possible personalized risk approaches 
might be used to characterize these risks. It is important to point 
out that these excess risks also raise important ethical issues that 
are beyond the scope of this article (5).
The inclusions of age at exposure, sex, and smoking status 
in setting radiation dose limits can be viewed as steps toward 
personalizing risk assessments. There are additional approaches, 
either feasible or currently available, that could further person-
alize these assessments. Personalized risk calculations could 
potentially be used for pre-employment screening to select crew 
members for particular flights or could be provided to crew mem-
bers and their flight surgeons for personal medical counseling 
with confidentiality safeguards. The legal issues raised by each of 
these uses are discussed below.
This article considers evidence that inter-individual differ-
ences contribute to cancer risk from radiation exposures, how 
these differences can be detected and how the information 
might be used. In addition, this article discusses how potential 
approaches for the detection of inter-individual differences in 
susceptibility to radiogenic cancer could impinge on the federal 
Genetic Information Non-discrimination Act of 2008 (GINA) 
and explores whether an employer (i.e., NASA) could lawfully use 
the information in employment or work assignment decisions.
Cancer risk is not generic. There are specific cancers that pose 
the greatest risks of exposure induced death. Using calculated 
REIDs from NSCR 2012 for 45-year-old male and female astro-
nauts [Tables A3 and A7 in Ref. (2)], the greatest risks are for 
lung, stomach, colon, ovarian, breast, liver, and bladder cancers 
for females, and lung, colon stomach, bladder, liver, and prostate 
cancers for males. Leukemia is also a risk for both sexes. Each of 
these tumor types is likely unique in the extent to which suscepti-
bility to them differs between individuals and in their amenability 
to preclinical detection.
approaCHes
personal and Family Medical History
Relative risk and absolute risk models and combinations of the 
two are used in risk calculations. Relative risk is calculated as a 
dose-dependent multiple of the background incidence of a cancer, 
whereas absolute risk is an added number of cases per unit dose 
that is independent of the background incidence. Which model 
best fits epidemiological data depends on the tumor type being 
modeled. The relative risk model assumes that radiation increases 
the incidence of spontaneous tumors and implicit in that assump-
tion is that radiogenic cancers are the same or nearly the same as 
their spontaneous counterparts. There is evidence that the relative 
risk model reflects biological reality for at least some radiogenic 
cancers. The few radiogenic tumors that have been characterized 
carry the same cytogenetic and molecular aberrations as a subset 
of spontaneous tumors of the same histotype (6–11). For example, 
sporadic acute myeloid leukemias (AML) have a range of recur-
rent chromosomal aberrations, predominantly translocations. 
However, radiation-induced AML are generally associated with 
deletions on chromosome 5 and/or 7 (11), cytogenetic lesions 
that occur in only a few percent of sporadic AML (12). The most 
plausible explanation is that radiation can contribute a step or 
steps to some of the pathways leading to sporadic leukemias (e.g., 
those involving chromosome 5 or 7 deletions), but radiation is 
ineffective in complementing other leukemogenic pathways.
If the goal is to move from a population-based risk calcula-
tion to a personalized risk calculation for setting permissible 
space radiation doses for an individual astronaut, one possible 
approach would be to use the astronaut’s background risk in place 
of the population background risk as the baseline for relative risk 
calculations. Individuals differ in their susceptibility to spontane-
ous cancers due to a number of factors related to lifestyle, genetic 
background, and poorly characterized environmental exposures. 
For example, a family history of some cancers (e.g., colorectal 
and breast cancer) confers greater risk. An individual with a 
first degree relative diagnosed with a colorectal cancer (CRC) is 
2.4-fold more likely to develop CRC than someone without an 
affected relative (13). For that matter, the monozygotic (identical) 
twin of a man with colon cancer has about a 7-fold greater risk 
of developing colon cancer than a man with an unaffected twin, 
for woman with an affected monozygotic twin the risk is about 
14-fold (14).
Risk calculators are readily available for some sporadic can-
cers. Several have been developed that assess individual breast 
cancer risk based on combinations of inputs on family history of 
breast and ovarian cancer, current age, race or ethnicity, breast 
biopsy history, age at menarche, breast tissue mammographic 
density, and reproductive history (15). Potentially, some of these 
inputs might be useful in personalizing radiogenic breast cancer 
risk calculations. Risk calculators are also available for CRC 
(16–18). The information input into these calculators includes 
family history, sex, current age, race and ethnicity, diet, body 
mass index, screening history, polyp history, use of aspirin, 
non-steroidal anti-inflammatory drugs, oral contraceptives and 
estrogen replacement, physical activity, smoking, and alcohol 
consumption.
Synopsis
Individual risk of radiation carcinogenesis might be more 
accurately calculated by including family history of cancer and/
or personal medical history including a history of colon polyps 
or breast biopsies. An assumption in this approach is that breast 
or colon cancer risk from space radiation exposure can be pre-
dicted, at least partly, from background risk by a transfer model 
incorporating multiplicative risk. In the current risk model, this 
assumption is made for CRC through the use of a mixture model 
(0.7 multiplicative and 0.3 additive) [Ref. (2), p. 80]. An additive 
model is used for breast cancer because it better fits results of a 
meta-analysis, not because of a biological basis.
detection of preneoplastic Cells and 
dormant Microtumors
Preneoplastic cells and dormant microtumors are frequently 
detectable in clinically normal individuals (19, 20), and it has 
been proposed that radiation exposure can lead to their promo-
tion and/or progression. The best evidence for this comes from 
studies of leukemia. In 2005, Nori Nakamura advanced the 
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hypothesis some individuals harbor clones of hematopoietic cells 
with preleukemic mutations and consequently are susceptible to 
radiogenic leukemias (21). The putative mechanism is that radia-
tion exposure induces additional leukemogenic mutations in the 
preleukemic cells leading to overt disease. Nakamura’s hypothesis 
is based on epidemiological investigations of leukemia in atomic 
bomb survivors and the findings of Mori et al. (22) showing that 
leukemia relevant translocations can be detected in the blood 
of about 1% of newborns, the vast majority of whom will never 
develop leukemia.
The detection of preleukemic cells in peripheral blood samples 
from some clinically normal individuals has been extended to 
adults [e.g., Ref. (23–25)]. Data from large-scale whole exome 
sequencing studies using peripheral blood cells as a DNA 
source have been mined to identify individuals that carry clonal 
expanded somatic mutations in leukemia related genes. The 
frequency of people harboring these cells increases with age 
and is associated with an increased risk of hematopoietic cancer 
(26, 27). That increased risk suggests that at least some of the 
mutations detected in mature circulating blood cells occurred in 
stem or progenitor cells primitive enough to undergo leukemic 
transformation.
Perhaps the best evidence for the existence of preleukemic 
cells that can be driven to complete leukemic transformation by 
exposure to a genotoxic agent comes from recent observations by 
Wong and coworkers (28). Radiation-induced AML commonly 
carry TP53 mutations. Wong found that two patients who devel-
oped AML following cytotoxic chemotherapy had identical TP53 
mutations in their leukemic cells and in blood samples collected 
prior to therapy. The likely explanation is that preleukemic cells 
(those with TP53 mutations) progressed to frank leukemia as a 
consequence of cytotoxic chemotherapy, and the inference is that 
radiation exposure could have a similar effect.
Screening individuals for preleukemic cells using peripheral 
blood samples can be accomplished with existing technologies, 
either SNP arrays for genomic gains or losses or uniparental 
disomy, or next generation sequencing for defined mutations in 
clonal populations.
Some pre-invasive tumors can be detected in  situ, with 
mammography for the detection of ductal carcinoma in  situ 
and colonoscopy for the detection of adenomatous polyps being 
commonly used screens. Whether these neoplasias can be driven 
to malignancy by radiation exposure are unknown at this time 
and, consequently, the value of pre-exposure screening to lower 
radiogenic cancer risk is also unknown.
New early detection methods for a range of cancers are being 
clinically evaluated, and some examples that are relevant for tumor 
types of greatest interest for space flight are briefly mentioned 
here. Promising results have been reported for a CRC early detec-
tion test based on the identification of mutant KRAS sequences in 
DNA from tumor cells shed into stool. The assay is less intrusive 
than colonoscopy and therefore more likely to be used. Mammary 
epithelial cells are accessible for cytological screening for prema-
lignant cells (29), and the test is offered to women at high risk for 
breast cancer. Its predictive value has not yet been established, 
but there are ongoing investigations on this approach including 
the incorporation of biomarker detection in the test. Low-dose 
computerized tomography (LDCT) lung cancer screening has 
been shown to decrease lung cancer mortality in heavy smokers 
or former smokers (30). LDCT frequently detects lesions in non-
smokers, but whether these lesions are dormant microtumors 
that can be promoted by radiation exposure is unknown.
Synopsis
Assays are currently available or in development for the detec-
tion of preneoplastic cells or dormant microtumors that could 
potentially undergo promotion or progress to frank cancer as a 
consequence of radiation exposure. Individuals with these incipi-
ent malignancies may be at higher risk for radiogenic cancer than 
those without. The various testing procedures involve simple 
imaging, the detection of overexpressed or aberrant proteins, or 
the detection of somatic mutations in DNA from cells collected 
using minimally invasive techniques. The potential of premalig-
nant cells or dormant microtumors to progress as a consequence 
of radiation exposure is not known.
phenotypic assays of sensitivity
The development of cell-based assays to identify radiation 
oncology patients sensitive to normal tissue injury has been an 
area of active research for many years. A logical extension of 
this research would be the development of assays for the iden-
tification of individuals susceptible to radiogenic cancers (or 
treatment-induced second malignant neoplasms in the context 
of radiation oncology). Cells collected from different individuals 
and irradiated ex vivo vary in their radiation responses as meas-
ured by endpoints putatively related to cancer such as clonogenic 
survival, DNA repair efficiency, transcriptional changes, number 
of cytogenetic aberrations, and proportion of cells undergoing 
apoptosis. Whether the inter-individual differences for any of 
these radiobiological endpoints predict inter-individual differ-
ences in susceptibility to radiogenic cancer is still speculative, 
but two assays are particularly interesting because they identify 
a sizable proportion of the population as being mildly radiation 
sensitive and are associated with sporadic cancer risk.
The G2 chromosomal radiosensitivity assay, which measures 
chromosome aberrations in cells irradiated in the G2 phase of the 
cell cycle, identifies about 5–10% of clinically normal individu-
als and about 40% of breast cancer patients as having enhanced 
chromosomal radiosensitivity (31, 32). The low dose rate (LDR) 
gamma-H2AX assay is based on quantifying residual DNA 
double strand breaks in cultured cells that have been irradiated at 
LDR. Fibroblasts from about 40% of clinically normal individuals 
fall in the mildly sensitive range, as do individuals heterozygous 
for ATM mutations, a group that has an elevated risk of breast 
cancer. Hereditary retinoblastoma patients who are at risk of 
second malignancies in the treatment field if they are treated with 
radiotherapy are also mildly sensitive in this assay (33, 34).
Human tumors and some human normal tissues can be propa-
gated long term in immunosuppressed mice. Mice carrying human 
tumors from individual patients (patient derived xenografts) 
have been used to test the efficacies of alternative treatment regi-
mens with the aim of tailoring treatment to specific tumors, thus 
personalizing cancer therapy. An obvious next step is the use of 
mice harboring normal human tissues to personalize radiogenic 
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cancer risk assessments. The advantage of irradiating human tis-
sue samples maintained in mice as compared to irradiating tissue 
samples in culture is that the tissue samples in mice would be 
in a more physiological setting and could be assayed long after 
irradiation. For example, NASA is currently supporting research 
that involves irradiating mice with human hematopoietic systems 
(so-called “humanized” mice) and monitoring the human cells 
for leukemia related endpoints. While this research is designed 
to explore the effects of simulated space radiation on the human 
hematopoietic system, it raises the possibility of using the same 
system to assess individuals for susceptibility to radiation-induced 
leukemia. Mice can be humanized using hematopoietic stem cells 
mobilized into the peripheral blood of donors by treatment with 
GCSF. These mice could be exposed to radiation and their human 
hematopoietic cells monitored for preleukemic changes such as 
mutations or chromosomal aberrations associated with leukemia 
with the goal of identifying donors whose hematopoietic cells had 
higher or lower frequencies of such changes.
Synopsis
Assays are under development that would use cells collected 
from individuals and irradiated ex vivo to determine susceptibil-
ity to radiogenic cancer. The endpoints in these assays will not 
be cancer per se, but surrogates for cancer susceptibility such as 
persistent DNA repair foci, chromosomal aberrations, or tumor 
associated mutations.
Genotypic assays of sensitivity
It has been known at least since the mid-1950s that some murine 
inbred strains are more susceptible to specific radiogenic can-
cers than others (35). The most likely explanation for the strain 
differences in susceptibility is the genetic differences between 
the strains, an explanation that is strongly supported by the 
identification of some of the genetic polymorphisms responsible 
(36–38). There are multiple lines of evidence that the genetic 
susceptibility to radiation-induced cancers observed in mice 
extends to humans.
It is fairly straightforward to demonstrate that humans differ 
for radiation responses and the differences are, in part, heritable. 
Twin studies show a greater concordance for radiobiological 
endpoints between monozygotic twin pairs than between 
dizygotic twin pairs. The reasoning behind these studies is that 
monozygotic twin pairs share their entire genome whereas 
dizygotic twin pairs share only about half of their genomes, 
but both monozygotic and dizygotic twin pairs share the same 
environments. A greater concordance for a trait, such as the per-
centage of lymphocytes that undergo radiation-induced apop-
tosis, between monozygotic twin pairs than dizygotic twin pairs 
would be due to their greater genetic similarity. The endpoints 
that have been assayed and found to be under genetic control 
are chromatid breaks following irradiation of PHA-stimulated 
peripheral blood cells (39), radiation-induced apoptosis (40, 41), 
and radiation-induced cell cycle delay (41). These endpoints are 
potentially related to radiation carcinogenesis, but the findings 
are only suggestive that susceptibility to radiation-induced 
cancer is a heritable trait.
Perhaps the first epidemiological data suggesting there might 
be a heritable component to susceptibility to radiation-induced 
cancer was the finding of a high risk for breast cancer diagnosed 
before age 35 in A-bomb survivors suggesting interaction between 
radiation exposure and genetic susceptibility to early onset breast 
cancer (gene and radiation interaction) in a subgroup of women 
(42). More recently, a study of families in which multiple members 
had been irradiated for treatment of tinea capitis found familial 
aggregation of radiation-associated meningiomas (43) suggestive 
of genetic susceptibility.
Evidence for genetic susceptibility to radiogenic cancers also 
comes from clinical observations of patients with rare, herit-
able cancer syndromes. In these examples, increased risks of 
radiation-induced cancers are linked to mutations (albeit rare 
mutations) in known genes. Hereditary retinoblastoma patients 
have a high incidence of sarcomas, which is further elevated by 
radiotherapy (44–46), children with neurofibromatosis type I 
treated with radiation for optic pathway gliomas are at increased 
risk for second nervous system tumors (47), and Gorlin’s syn-
drome patients treated with radiotherapy develop basal cell 
carcinomas in the treatment field (48). The early onset and high 
penetrance of retinoblastoma makes it highly unlikely anyone 
with the heritable form of the disease would be selected for the 
astronaut corps (though de novo mutations resulting in somatic 
mosaicism mean the possibility cannot be completely excluded). 
While the association of some rare heritable syndromes with 
increased risk for radiation-induced cancers is interesting, the 
real questions are whether susceptibility occurs in the absence of 
readily identifiable syndromic disease in clinically unremarkable 
individuals and whether susceptible individuals are extremely 
rare or common.
Some common genetic polymorphisms associated with 
increased or decreased risks of radiogenic cancers have been 
identified in genetic association studies (49–54). A limitation of 
this approach is that the polymorphisms detected are limited to 
those selected for the studies, which are in genes known to be 
mutated in cancer or related to response to ionizing radiation-
induced DNA damage.
Genome-wide association studies (GWAS) avoid the bias 
toward genes considered likely to influence radiosensitivity 
by screening the entire genome. However, GWAS studies of 
spontaneous cancers typically yield modest risk estimates, an 
observation fueling skepticism about their use in studies of 
radiogenic cancers. There are two reasons why GWAS associa-
tions in radiation-induced cancers may prove to be stronger. The 
first is that associations become stronger as the tumor subtype 
is more rigorously defined. There is reason to believe that radio-
genic tumors only arise along a subset of oncogenic pathways 
(see the example of radiation-induced AML above), so GWAS 
associations for radiogenic tumors may be stronger because 
these tumors are genetically less diverse. The second reason to 
expect stronger associations with radiogenic than spontaneous 
tumors is that association studies for adverse drug reactions often 
yield strong associations with relatively few cases. An explana-
tion that has been advanced for this observation is that a single 
strong environmental input decreases the background of other 
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environmental causes that may operate in conjunction with other 
susceptibility loci (55). For example, in a study of Hodgkin’s lym-
phoma patients treated with radiotherapy, Best et al. identified a 
haplotype on chromosome 6q21 that was strongly associated with 
second malignant neoplasias. PRDM1 emerged from the study as 
a candidate gene (56).
Whether genotypic assays of radiosensitivity can improve the 
precision of risk assessment will depend on a number of factors. 
One is the extent to which heritable sequence variants deter-
mine cancer risk from high LET exposures. High LET radiation 
exposures result in more complex molecular lesions that are less 
amenability to repair [see Ref. (2) section 5.2]. Thus, it could be 
argued that sequence variants that result in subtle differences 
in DNA repair and damage response pathways would have a 
lessor impact on high LET radiation carcinogenesis. However, 
there are profound murine and rat strain (or stock) differences 
in susceptibility to specific tumor types induced by high LET 
radiation and at least one polymorphism controlling high LET 
carcinogenesis has been identified (37). These observations 
point to a role for sequence variants in determining high LET 
radiation risks.
Synopsis
Polymorphisms in the human genome have been associated 
with risks for radiogenic cancers in atomic bomb survivors, 
radiological technologists, radiotherapy patients and people with 
environmental radiation exposures. Whether genotyping for 
these susceptibility associated polymorphisms and others that 
are sure to be discovered in the future will identify individuals 
at higher risk for cancer from the types of radiation exposures 
experienced space flight is currently unknown.
postFlight Monitoring
The NASA REID for radiation-induced cancer is not for all can-
cers, but rather for fatal cancers. Early detection reduces mortality 
for some tumor types [for the influence of tumor stage on mortal-
ity see Ref. (2), p. 51]. Regular postflight early detection cancer 
screening might therefore be expected to lower the risk of cancer 
death as a consequence of space radiation exposure assuming, of 
course, that radiogenic cancers are similar to their spontaneous 
counterparts. Early detection screens for breast, colorectal, and 
prostate cancer are already a routine part of medical care in the 
US. The relative benefits and risks of mammography screening 
for breast cancer, particularly before 50  years of age, and of 
prostate-specific antigen-based screening for prostate cancer are 
contentious. However, colonoscopy screening with polypectomy 
demonstrably reduces CRC incidence and mortality in patients 
with Lynch Syndrome, a heritable CRC syndrome (57–60), and 
also reduces sporadic CRC deaths (61). Progression from adenoma 
to carcinoma is accelerated in syndromic CRC, so patients with 
Lynch syndrome are screened at 1- or 2-year intervals. Whether 
standard screening intervals would be adequate to reduce CRC 
risk for an individual with a history of sizable exposures to space 
radiation is unknown.
Based on the National Lung Screening Trial (NLST), LDCT 
lung cancer screening decreases lung cancer mortality in current 
and former smokers (30). However, LDCT is not yet a routine 
test, it requires a high level of expertise to perform. Also, there 
are risks from overdiagnosis and false-positive results. These risks 
are important considerations because the benefits of LDCT were 
assessed in smokers and former smokers that varied widely in 
their risks for lung cancer (62) but were generally at much higher 
risk of lung cancer than that calculated for astronauts exposed to 
even maximum permissible radiation doses [Tables A1 and A5 
in Ref. (2)]. An added consideration, which may be particularly 
relevant if LDCT were used to screen radiation exposed individu-
als, is additional radiation exposure from the scans themselves 
(63, 64).
Synopsis
Early detection can lower mortality for some tumor types. This 
reduced mortality can be incorporated in the current NASA risk 
model through adjustments to the incidence to mortality ratios 
for different tumor types. Doing so assumes that early detection 
of radiation-induced tumors leads to the same reduction in 
mortality as for sporadic tumors and that astronauts and former 
astronauts actually undergo early detection screenings.
appLiCaBiLity oF Gina to 
personaLiZed CanCer risK 
approaCHes
As a federal agency, NASA is required to furnish its employees 
with a workplace that is free from recognized hazards such as 
ionizing radiation that are causing, or likely to cause, death or 
serious physical harm (65). NASA is also required to establish 
and operate an occupational safety and health program to protect 
workers. Recognizing the unique needs of space exploration, the 
federal Occupational Safety and Health Administration (OSHA) 
granted NASA a waiver from ground based radiation standards 
while requiring it to establish supplemental standards appropriate 
for space missions (1, 66). NASA’s Office of the Chief Medical and 
Health Officer is responsible for setting these standards, and issued 
a series of documents including NASA Procedural Requirements 
(NPR) 8900.1A (NASA Health and Medical Requirements 
for Human Space Exploration) and NPD 8900.5B (Health and 
Medical Policy for Human Space Exploration) in response (67, 
68). In addition, NASA STD-3001, chapter 6, explicitly addresses 
ionizing protection in space environments (69).
overview of Gina
The GINA, codified as 42 US §§2000ff, is a federal law that 
prohibits employment discrimination on the basis of genetic 
information (70). This statute has two major sections. Title I 
covers group health plans and insurers. Title II covers employers, 
such as NASA, and prohibits them from discriminating against 
employees and job applicants based on genetic information. It also 
prohibits employers from collecting genetic information, except 
under very limited circumstances. The US Equal Opportunity 
Employment Commission (EEOC), an independent commission 
charged with enforcing federal laws against job discrimination, 
taBLe 1 | summary of approaches to personalized cancer risk assessments.
approach Underlying concept examples of marker or data used
Personal/family medical 
history
For some tumor types radiogenic cancer risk is determined, in part, by 
background risk
Family or personal history of cancer, intestinal polyps, breast 
biopsies
Detection of preneoplastic 
cells, dormant microtumors
Preneoplastic cells and microtumors can be detected in clinically 
normal individuals; some of these can undergo promotion or 
progression due to radiation exposure
Blood or tissue aspirates assayed for cancer related 
mutations or biomarkers; in situ detection of pre-invasive 
tumors by imaging
Phenotypic assays of 
sensitivity
Radiogenic cancer susceptibility can be due to a number of genetic 
and non-genetic causes; ex vivo radiosensitivity assays of cells or 
tissues are agnostic in regard to the cause of susceptibility
LDR gamma-H2AX and G2 chromosomal radiosensitivity 
assays using peripheral blood cells or fibroblasts; cancer 
biomarker detection in cells or tissues irradiated in 
humanized mice
Genotypic assays of 
sensitivity
Individuals vary in their susceptibility to radiogenic cancer due to their 
genetic backgrounds
Genomic sequence polymorphisms 
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oversees GINA and has issued regulations to implement it (see 
29 CFR §§1635.1 to 1635.12) (71). This article focuses on Title 
II of GINA and examines how its provisions could impact the 
implementation of the four approaches to personalized cancer 
risk assessments, summarized in Table 1 and set out earlier in 
this article.
This statute and its implementing regulations are relatively 
new, and interpretation of its provisions is evolving [e.g., Ref. 
(72)]. The discussion of the applicability of GINA to NASA is 
based on the information available at the time of publication, and 
it is possible that subsequent events, especially litigation brought 
under GINA, could impact the way in which GINA is interpreted. 
The analyses are based on generalized circumstances and are not 
intended to provide legal advice.
One of the central provisions of GINA is that “it is an unlawful 
employment practice for an employer to request, require, or pur-
chase genetic information with respect to an employee” [42 USC 
§2000ff-1(b)]. This provision turns on how the statute defines the 
term “genetic information.” Under GINA, this term means infor-
mation about an individual that includes “(i) such individual’s 
genetic tests, (ii) the genetic tests of family members of such 
individual, and (iii) the manifestation of a disease or disorder in 
family members of such individual” [42 USC §2000ff(4)]. In addi-
tion, the term “genetic test” is “an analysis of human DNA, RNA, 
chromosomes, proteins, or metabolites, that detects genotypes, 
mutations, or chromosomal changes” [42 USC 2000ff(7)].
Collecting and Using personalized 
information for space radiation risk 
assessments
This article discusses four approaches to supplement personalized 
cancer risk assessments. The first approach would incorporate 
family and personal medical history, especially for breast cancer 
and CRC, into these assessments. The second approach would 
collect information about microtumors or preneoplastic cells 
that could undergo promotion and/or progression by radiation 
exposures to malignancies. The third and fourth approaches 
would rely on evaluations of radiosensitivity based on genotypic 
and phenotypic assays. Each of these approaches would seem to 
trigger the collection of genetic information under GINA and 
therefore would most likely be prohibited under the statute. 
The first approach falls squarely within GINA’s prohibition of 
collecting personal and family medical information. The second 
approach would rely on the evaluation of cells and tissues based 
on their mutations, which also is a prohibited activity under 
GINA. The third and fourth approaches are keyed to radiosensi-
tivity or genotype to phenotype associations, which again would 
require the collection of data that falls squarely within GINA’s 
purview. In summary, based on GINA’s intent and its statutory 
language, it appears that the data and methodologies set forth in 
this article that would be needed for personalization of cancer 
risk assessment would be prohibited by GINA. More specifi-
cally, under GINA it seems clear that NASA could not collect 
nor use to make employment decisions, information based on 
personalized cancer risk assessments that use the approaches 
set out in Table 1.
Two potential uses of more personalized cancer risk assess-
ments are to screen NASA applicants and reduce employment 
risks to astronauts who are sent on space missions. GINA 
prohibits the use of genetic information and genetic tests for 
pre-employment screening. As this article points out, at present 
NASA’s approach to setting permissible exposure limits relies 
on a cancer risk assessment model that takes into account the 
astronaut’s age at exposure, sex, and smoking status. From a 
scientific perspective, this article suggests that among the steps to 
model improvement would be to utilize the increasingly powerful 
and more precise technologies that employ what, under GINA, 
would be classified as “genetic information” and “genetic tests.” 
Construing the statute as currently interpreted, it would seem 
that collecting and using this information would contravene this 
law and its regulations.
postFlight Monitoring and Gina
This article also suggests that postflight monitoring is poten-
tially beneficial for astronauts. Such monitoring could result in 
reduced mortality for some tumor types, because early detection 
of tumors or pre-cancerous conditions could mean more effec-
tive, and timely, intervention. In this regard, GINA contains an 
exception to the collection of genetic information for employers 
who want to collect such information to assess the biological 
effects of toxic substances in the workplace. The employer can 
offer health and/or genetic services to employees in the form 
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of a confidential wellness and/or counseling program. GINA 
requires that such information can be collected and used if 
the employee provides voluntary written authorization before 
collection; only the employee and family members and the 
genetic counselor receive this information; and that the indi-
vidual genetic information not be disclosed to employers [42 
USC §2000ff-1(b)(5)]. Under this section of GINA, it might be 
possible to collect and use the type of genetic information that 
is contemplated by the approaches outlined in this article. Such 
information might be disclosable to NASA “only in aggregate 
terms that do not disclose the identity of specific employees” 
[42 USC §2000ff – 1(b)(5)(E)].
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